Role of hepatokines in non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic diseases like type 2 diabetes and obesity. In recent decades, accumulating evidence has revealed that the hepatokines, proteins mainly secreted by the liver, play important roles in the development of NAFLD by acting directly on the lipid and glucose metabolism. As a member of organokines, the hepatokines establish the communication between the liver and the adipose, muscular tissues. In this review, we summarize the current understanding of the hepatokines and how they modulate the pathogenesis of metabolic disorders especially NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235 · cited 1×
“Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, which affects approximately up to 33% adult population.[1,2] NAFLD is defined by the accumulation of lipids in the liver, in the absence of excessive alcohol consumption, viral hepatitis and other causes of hepatic steatosis,…”
BackgroundBadman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Self-citationFibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031
Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance
Pal, D., Dasgupta, S., Kundu, R., Maitra, S., Das, G., Mukhopadhyay, S., Ray, S., Majumdar, S. S., & Bhattacharya, S. (2012) · Nature Medicine · doi:10.1038/nm.2851 · Cited by 922 · cited 1×
“[19] On the other hand, fetuin-A is reported with involvement in low-grade inflammation in NAFLD, acting as an endogenous ligand and scaffold protein for toll like receptor 4 (TLR4), which further promoted the lipid-induced pro-inflammatory response and insulin resistance.[20,21] Fetuin A was also found to greatly pro…”
BackgroundThe effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · cited 2×
“LY2405319 could significantly alleviate insulin resistance, overweight and obesity, and reduce adiponectin level in patients.[47] However, the efficacy of FGF21 in treating metabolic disorders needed to be verified by large-scale and multi-centered trials in the future.”
BackgroundIdentification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847
Fon Tacer, K., Bookout, A. L., Ding, X., Kurosu, H., John, G. B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D. J., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0142 · Cited by 700 · cited 1×
“Fibroblast growth factor 21 (FGF21) is a 209-amino acid protein mainly secreted by the liver, which can also be detected in pancreas, testis and adipose tissues.[24,25] Growing evidence suggested that FGF21 was a protective factor acting through glucose and lipid metabolism in an insulin independent manner.”
BackgroundThe Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00034 · Cited by 615 · cited 1×
“In the recent decades, accumulating evidence revealed that liver may modulate the processes of NAFLD and other metabolic co-morbidities by secreting hepatokines, including fetuin-A, angiopoietin-related growth factor (AGF), fibrosis growth factor 21 (FGF 21), insulin-like growth factors (IGF), selenoprotein P (SeP), l…”
BackgroundIncreased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607
A liver-derived secretory protein, selenoprotein P, causes insulin resistance
Misu, H., Takamura, T., Takayama, H., Hayashi, H., Matsuzawa-Nagata, N., Kurita, S., Ishikura, K., Ando, H., Takeshita, Y., Ota, T., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.09.015 · Cited by 583
Fibroblast Growth Factor 21-Deficient Mice Demonstrate Impaired Adaptation to Ketosis
Badman, M. K., Koester, A., Flier, J. S., Kharitonenkov, A., & Maratos-Flier, E. (2009) · Endocrinology · doi:10.1210/en.2009-0532 · Cited by 362 · cited 1×
“[43] FGF21-deficient mice showed an impaired glucose homeostasis and weight gain.[44] Moreover,”
BackgroundFisher, F. M., Chui, P. C., Nasser, I. A., Popov, Y., Cunniff, J. C., Lundasen, T., Kharitonenkov, A., Schuppan, D., Flier, J. S., & Maratos-Flier, E. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.044 · Cited by 263 · cited 9×
“[39] Consistent with this opinion, studies found that exogenous introduced FGF21 may help slow the progression of NAFLD.”
BackgroundInfluentialPerry, J. R. B., Weedon, M. N., Langenberg, C., Jackson, A. U., Lyssenko, V., Sparsø, T., Thorleifsson, G., Grallert, H., Ferrucci, L., Maggio, M., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp522 · Cited by 217 · cited 2×
“However, the level of circulating SHBG has also been shown to be associated with glucose metabolism, quantity of the adipose tissue and metabolism disorders.[57,58] The SHBG level in the liver and peripheral was significantly lower in patients with hepatic steatosis, where serum SHBG was found to be negatively associa…”
BackgroundYang, S. J., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0620 · Cited by 191
Misu, H., Takayama, H., Saito, Y., Mita, Y., Kikuchi, A., Ishii, K.-A., Chikamoto, K., Kanamori, T., Tajima, N., Lan, F., et al. (2017) · Nature Medicine · doi:10.1038/nm.4295 · Cited by 156
Kim, S. H., Kim, K. H., Kim, H.-K., Kim, M.-J., Back, S. H., Konishi, M., Itoh, N., & Lee, M.-S. (2015) · Diabetologia · doi:10.1007/s00125-014-3475-6 · Cited by 124 · cited 9×
“[39] Consistent with this opinion, studies found that exogenous introduced FGF21 may help slow the progression of NAFLD.”
BackgroundInfluentialHepatokines and non-alcoholic fatty liver disease
Lebensztejn, D. M., Flisiak-Jackiewicz, M., Białokoz-Kalinowska, I., Bobrus-Chociej, A., & Kowalska, I. (2016) · Acta Biochimica Polonica · doi:10.18388/abp.2016_1252 · Cited by 90 · cited 1×
“In the recent decades, accumulating evidence revealed that liver may modulate the processes of NAFLD and other metabolic co-morbidities by secreting hepatokines, including fetuin-A, angiopoietin-related growth factor (AGF), fibrosis growth factor 21 (FGF 21), insulin-like growth factors (IGF), selenoprotein P (SeP), l…”
BackgroundSex Hormone-Binding Globulin Reduction in Metabolic Disorders May Play a Role in NAFLD Development
(2017) · EndocrinologyJN · doi:10.1210/en.2016-1668 · Cited by 71
Takata, H., Ikeda, Y., Suehiro, T., Ishibashi, A., Inoue, M., Kumon, Y., & Terada, Y. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.no950 · Cited by 66
Cited by
Epidemiology of metabolic dysfunction-associated steatotic liver disease
Younossi, Z. M., Kalligeros, M., & Henry, L. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0431 · Cited by 960
Hepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252
“Furthermore, fetuin-A is a negative regulator of the adipokine adiponectin and organokines work in concert to regulate insulin resistance (Figure 3) [121,124,125].”
BackgroundThe role of FGF21 and its analogs on liver associated diseases
Falamarzi, K., Malekpour, M., Tafti, M. F., Azarpira, N., Behboodi, M., & Zarei, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.967375 · Cited by 94
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
“The mechanisms responsible for the link between NAFLD and T2D are not completely understood but could include genetic factors, insulin resistance, dysfunctional adipose tissue, chronic hyperglycemia, altered gut microbiome, and changes in hepatokines, among others (68, 69).”
Background
Metadata
- Authors
- Ke, Y., Xu, C., Lin, J., & Li, Y.
- Venue
- Journal of Translational Internal Medicine
- Publisher
- Walter de Gruyter GmbH
- Published
- 2019-12-01
- Volume
- 7
- Issue
- 4
- Pages
- 143-148
- ISSN
- 2224-4018 (ISSN-L)
- OpenAlex
- W3001370696
- Cited by
- 46
- References
- 20
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.